---
title: "Aldeyra Therapeutics, Inc. (ALDX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALDX.US.md"
symbol: "ALDX.US"
name: "Aldeyra Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T20:48:18.993Z"
locales:
  - [en](https://longbridge.com/en/quote/ALDX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALDX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALDX.US.md)
---

# Aldeyra Therapeutics, Inc. (ALDX.US)

## Company Overview

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.aldeyra.com](https://www.aldeyra.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.42 | 314 | - | - | - |
| PB | 2.22 | 202 | 6.32 | 5.60 | 2.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Overweight | 1 | 20% |
| Hold | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.59 |
| Highest Target | 13.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALDX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALDX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ALDX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALDX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**